Krause Lab

University of Otago


  • Enhancing Innate Immunity to HIV
  • AIDS remains an incurable global pandemic that is becoming more resistant to available treatments. Current treatments for those suffering from HIV/AIDS involve of a combination of anti-retroviral drugs targeting the HIV protease, reverse transcriptase, and integrase proteins, as well as a number of newer therapeutic targets. Combination therapy significantly reduces the rate at which resistance develops, however, no cure is currently available and with increasing HIV resistance, the development of new treatment strategies targeting the HIV virus continues to be a priority.  Read more >>
  • Viral Chemokine Binding Proteins
  • Pox viruses and herpes viruses have evolved numerous strategies to evade the host immune system and ensure their own survival. They often viruses encode secreted chemokine binding proteins (CKBPs) that modulate inflammation by interfering with host chemokine signaling.  Read more >>
  • Mycobacterium Drug Targets
  • Mycobacterium tuberculosis is the pathogen that causes tuberculosis (TB). According to estimates of the World Health Organization, one third of the world’s population is infected with TB and the disease causes almost 2 million deaths per year. We are working on the development of novel chemotherapeutics that can be used to treat sensitive strains as well as the increasing problem of multi-drug resistant strains. To identify and characterize compounds that inhibit essential enzymes of M. tuberculosis we use fragment screening, enzyme kinetics, biophysical methods like SPR and ITC and structure-based drug design.  Read more >>
  • Influenza Neuraminidase
  • Influenza is an infectious disease responsible for severe illness and death, and capable of worldwide pandemics.  Read more >>
  • Bioluminescence
  • Our research group is studying the production of light by the New Zealand glowworm, Arachnocampa luminosa.  Read more >>